CGX1321, a novel WNT pathway inhibitor of Porcupine, represents a potential treatment for cancer and other WNT-driven diseases such as fibrosis. CGX1321 has completed the phase 1 clinical studies in the United States and China, and is undergoing efficacy dose-expansion and phase 1b combination with Keytruda clinical trials. To enroll in the following studies:
Curegenix is a clinical-stage company with operations in the San Francisco Bay Area and Guangzhou China. We focus on the discovery and development of novel drugs.